INTRODUCTION
Many patients with cystic fibrosis (CF) have thick and sticky sputum. Clearing the chest of these tenacious secretions is a daily ritual and a bind, but failure to do so contributes to the ongoing destructive cycle of infection, inflammation, obstruction, bronchiectasis and end-stage lung disease.
The airways have a highly sophisticated defence system, with protection provided by the ciliated epithelial cell layer , the surface airway liquid layer and the mucosal immune system. The airway surface layer consists of a periciliary liquid layer (sol) between and covering the cilia, and mucins secreted and assembled into a mucous gel in the extracellular space on the surface of the airways (the gel layer). This overlying mucous gel is composed of oligometric secreted mucins that interact with the cilia to form the mucociliary transport system 1 (Figure 1 ). Normal healthy mucus is composed of a mixture of glycocoprotein mucins, plasma-derived proteins, lipids, water, electrolytes and cellular debris. The rheological properties for optimal functioning demand a viscosity and elasticity within a narrow range, with sufficient adhesion and 'wettability' to facilitate spread over the epithelial laver-'. New evidence suggests that a layer of surfactant may lie at the cilia-mucus interface and assist in the ciliary coupling and transfer of mucus across the surface.
In CF, the abnormal cystic fibrosis transmembrane regulator (CFTR) function results in mucus hypersecretion, a volume-depleted periciliary surface liquid, and the possibility of altered electrolyte constituents 3 . The defects in electrolyte transport lead to dehydration of the airway mucus and an increase in viscosity". The airways become vulnerable to infection and inflammation, and the influx of white cells with the presence of bacterial debris produces a significant increase in the levels of DNA and actin.(Bo~l. DNA has an inherent property to form a gel and actm IS highly viscoelastic. In addition, the rai se~l i pĩ conten~~nd increased IgM concentration may also Impair mucociliarv clearance. These changes produce an altered tenacious mucus (sputum) which accumulates. The familiar cycle of infection, inflammation destruction and bronchiectasis begins.
The aim of mucolytic therapy is to reduce the viscosity, adherence and tenacity of the sputum and aid efficient clearance. A number of agents are in current use in CF, but how do they work and what is the evidence for clinical benefit? This article reviews the role of these mucolytics in cystic fibrosis.
THE SCIENCE IN STUDYING SPUTUM
A detailed description of the science of mucus biomechanics is beyond the scope of this article (and its author). It is, however, important to have an understanding of the terminology and investigative techniques used in the study of sputum rheology when assessing the results of trials on mucolytic agents. Some underlying principles are givcn in Box 2. Four rheological properties appear to contribute to an effective mucus layer and are altered in cystic fibrosis. These are:
• Viscosity-the flow characteristics • Elasticity-the deformation characteristic • Adhesiveness-of the mucus to the epithelial layer • Wettability-thc ease of spread over the epithelial surface.
These properties can be measured both in vitro and in vivo using a number of techniques:
• Bench tests with biomechanical measurements, e.g.: viscoelasticity by magnetic microrheometry using a magnetic oscillating sphere; spinnabilitv (a measure of thread formation in mm) using a Filancemeter; pourability assay-a qualitative assay of viscosity; time to thread relaxation • Bench tests using biological substrates, e.g.: in vitro mucociliary transport on frog palate or ferret trachea When assessing the results of efficacy trials for mucolytic agents in CF, it becomes important to examine carefully the outcome measures used, especially in comparative analyses.
MUCOACTIVE AGENTS
Mucoactive agents aim to alter the constituents of mucus.
Mucolytics are a subgroup that aims to thin the mucus and Product licensing has limited paediatric use to children over 5 years of age, but many centres will use DNase in selected younger children without concern-". A systematic review of rhDNase has been undertaken on behalf of the Cochrane collaboration. Seven clinical trials met the inclusion criteria, totalling 1710 patients. Metaanalysis of these trials has shown that DNase is a safe drug with very few side effects. There is an improvement in lung function (FEV,) in the treated group of 10.19± 1.42% for the trials of up to 1 month in duration. In those trials studying patients over a 6-month period there was an improvement in FEV) of 5.7±12.55%21.
Box 2 Rheological terminology for the beginner Box 1 Organic composition of sputum (mean % dry weight) 18 aid its clearance (Box 3). There are a number of products available that can assist in this process.
Recombinant human DNase (rhDNase)
DNase is a naturally occurring enzyme that is secreted in bodily fluids and is responsible for clearing up cellular debris by chopping up long strands of DNA into short pieces to facilitate their disposal. Tenacious CF sputum is transformed in vitro from a non-flowing gel to a flowing liquid by this action. Based on these observations, bovine pancreatic DNase 1 was approved for human use in the USA in 1958. Over the subsequent decade occasional severe adverse reactions led to a decline in its popularity '.
The development of a recombinant human form of this enzyme (rhDNase) led to a series of short-and long-term clinical trials that showed an improvement in lung function (forced expiratory volume in 1 s, FEV,) and a decrease in infective exacerbations in patients with CF6 9. Its introduction into clinical practice in the early 1990s led to considerable excitement within the CF community, and indeed sparked a renewed interest in the role of mucolytics in CF. The rapid move from bench to bedside for rhDNase led to conflicting opinions among practitioners: . an optimism for something 'new' that will improve lung function, but also considerable scepticism about "its true long-term role in improving pulmonary disease and outcomel" .'2. Concerns have also been raised that DNase therapy may simply mask underlying inflammation and actually increase the release of proinflammatory cytokines, such as free IL-8 13. Cleavage of DNA may result in a significant release of serine proteases, which may in turn cause enhanced proteolytic activity!". None the less, nebulized rhDNase has established itself as a benchmark for mucolytic therapy with an excellent safety record' 5 19 Mucoregulators: aim to increase secretion and restore volume, e.g. • Expectorants: hypertonic saline, mannitol • Ion channel modifiers: P2Y2 agonist therapy aim to thin mucus, e.g., • DNase, thiol agents (NAC), • Sodium 2-mercaptoethane sulphonate aim to improve cough clearability, e.g.,
• Bronchodilators • Adhesives like surfactants aim to thicken mucus, e.g.
• Tetracycline
aim to decrease secretion, e.g. • Anticholinergics (atropine, glycopyrrolatej • Glucocorticosteroids, indomethacin • Macrolide antibiotics
Hypertonic saline (HS)
Hypertonic saline at a concentration of 3% has been shown to enhance mucociliary clearance both in vitro and in vivo 27 . The postulated mechanisms include the following:
Hypertonic saline induces an osmotic flow of water into the mucus layer, rehydrating the mucus and improving its mucociliary clearance 2 In chronic infection, the mucin macromolecules develop fixed negative charges. HS shields the negative charges and reduces repulsion. The subsequent conformational changes lead to a more compact mucus macromolecule that promotes effective clearance 3 HS breaks the ionic bonds within the mucus gel and lowers the viscosity and e1asticit y 28 4 HS makes you cough! As part of a three-way comparative trial, Suri et al. 22 looked at the FEV t response of 43 children with CF to daily versus alternate-day DNase. There was no statistically significant difference between the two groups after 3 months of therapy. With a potential cost saving of 50%, this observation may require future consideration when reviewing the long-term use of DNase as a mucolytic.
A further multicentre trial using DNase in children aged 6-10 years with early lung disease has recently been completed and presented in abstract form 23 . This group of 474 children had lung function parameters above 80% of that predicted for height, and were randomized to placebo (n=235) or DNase (n=239). There was an 87% completion rate over the 2-year period. At week 96, DNase patients . had a 3% predicted treatment benefit in FEVI and a 34% reduction in the risk of exacerbation. This early intervention was safe in young well patients over the 2 year period. In selecting patients for DNase, a common practice has evolved. Most CF clinicians will consider its use in patients who are sputum producers with an FEV1 less than 70% of normal and in whom there is perceived difficulty in the removal of secretions or a declining lung function. A number of centres have now introduced a protocol for an nof-I trial (see below) to document individual benefit over the short term. Attempts at predicting the outcome for the individual patient on the basis of pretreatment clinical data have failed/", Some studies indicate that the results after 3 months' treatment with DNase predicts response at 12 months19, and many authors consider that if benefit is to be seen in the moderately affected patient this will be evident by 2--4 weeks. This treatment effect may not be as immediate in patients with severe lung disease (FVC < 40%), and a longer treatment period may be required.
The long-term benefit for DNase beyond 2 years is not yet established 2s , 26. A recent Cochrane review sought to determine whether nebulized hypertonic saline treatment improved lung function, exercise tolerance and quality of life and decreased the incidence of exacerbations in CF. Twelve controlled trials of HS in CF were identified and seven met the stringent criteria imposed by the authors. These trials involved 143 subjects with an age range of 6--46 years. The results were not uniformly favourable. There was some evidence for improved mucociliary clearance as measured by isotope markers. BecausF HS induces coughing in some patients, the effect of coughing on mucociliary clearance has also been studied to determine the possible confounding effect. In such studies each patient is asked to cough voluntarily, such that the number of cough manoeuvres performed is equal to or slightly greater than the maximum number of coughs recorded during the intervention period. The difference between cough alone and HS remained significant in favour of HS, and the improvement in mueociliary clearance by HS was not due to coughing alone-". The strength of hypertonic saline used varied between 3% and 12%, with benefit favouring more hypertonic solutions. No studies reported adverse side effects. The results of this review concluded that there is insufficient evidence to support the use of hypertonic saline in routine treatment for patients with CF30.
Nebulized HS can cause bronchoconstriction, and a bronchodilator is often given as combination therapy. In a study of nebulized 7% saline, Suri et al. 31 monitored percentage change in FEV 1 with the first dose of HS in 45 children with CF. Two children experienced a drop in FEVI of greater than 15%. One child withdrew from the 12-week trial because of subjective breathlessness. Fortyone patients were able to complete the course of therapy with no ill effect; 33 required additional bronchodilators-! ( Figure 2 ). 30 
Acetylcysteine (NAC)
N-acetyl-L-cysteine (Mucomyst, Parvolex) decreases sputum viscosity after inhalation and is used in the treatment of a variety of pulmonary disorders, including CF35. NAC depolymerizes mucus in vitro by breaking disulphide bridges between macromolecules. It is assumed that this reduction in sputum tenacity facilitates its removal from the respiratory tract. In CF sputum it also has protease activity.
Clinical studies have not borne out the mucolytic potential for NAC, showing either no change or even a decrease in lung function tests. Animal studies of its effect on ciliary function in cats and ferrets have shown a ciliostatic effect, with prolonged use resulting in complete ciliary paralysis. Both the ciliostatic and the mucolytic properties of the acetylcysteine molecule are dependent on the sulphadryl molecule, and analyses blame this compound for these two counterbalancing effects 36 • There are clinical problems described with the use of NAC. Bronchospasm is often reported''", it has a distinct and unpleasant sulphurous odour, and aerosolized NAC has a pH of 2.2. A systematic review of N-acetylcysteine in cystic fibrosis was undertaken using 23 studies (mostly observational-only three were randomized and controlled), but no evidence to support its use could be found 35. The three randomized controlled trials on nebulized NAC failed to show a statistically significant or clinically relevant beneficial effect 38. Oral administration was also reviewed, with no proof of clinical benefit over a 3-month period 35. There is no convincing evidence that oral NAC, even in high doses, has a useful clinical effect on sputum clearance, in spite of its theoretical possibilities 39 -42. In vitro studies have shown a potential role for NAC when used in combination with DNase 43. Recently, Nacetylcysteine has been produced in a dry powder inhaler device. A study looking at the effectiveness of NAC as an additive therapy in CF children currently treated with DNase was undertaken in a randomized multi centre doubleblind trial of 41 patients over a 12-week period. The group of patients taking NAC (8 mg twice a day) in addition to their DNase tolerated the drug well, but the study did not describe an improved efficacy in the use of these two complementary mucoactive agents 44 .
Sodium 2-mercaptoethanesulphonate
Sodium 2-mercaptoethanesulphonate (mesna/Mistabron) is a similar sulphadryl compound to NAC and is believed to reduce sputum viscosity by disrupting sulphide bonds. There is thin evidence from decades past that Mistabron may be more active than NAC both in vitro and in vivo 45 . One study of this agent showed a beneficial effect in children with CF using lung function parameters as thẽ % outcome measure when compared with HS (see below) . The effect of HS on airway inflammation and defence is unclear. The alteration in volume and possibly electrolyte constituents of the airway surface liquid is promulgated as a causative factor for both the infection and inflammation of the CF airway. If this hypothesis is correct, then HS has the potential to be harmful. However, the effect of HS on the ion concentration of the surface fluid is likely to be transitory, and any impact on defensin inactivation will be short-lived'". The rapid influx of water into the airway lumen along its osmotic gradient would soon counteract the effect of the HS. In addition, the role of defensins is almost certainly going to be a primary line of defence. Once suppurative lung disease is established, the beneficial effect of this mucolytic in assisting sputum clearance and removing the load of pathogens and degradative enzymes it contains is likely to be more beneficial than any theoretical impact on defensin function.
There is evidence that HS is a better mucolytic than normal saline. In a study using 10 adolescents with CF, 6% hypertonic saline was compared with normal saline to determine the effect on expectoration when inhaled before physiotherapy. HS increased sputum expectoration, although there was no difference in spirometry between the two groups33. The effect of hypertonic versus normal saline on short-term lung function in 52 patients with cystic fibrosis showed a significantly greater improvement in FEVI for the HS group (15 ± 16%) versus the normal saline group (2.8±13%; P=0.02)34. These improvements are similar to those seen with rhDNase.
Which strength of hypertonic solution is optimal? A small study comparing 3%, 7% and 12% HS showed a significant increase in mucociliary clearance for all HS solutions over controls, with 7% and 12% producing marginally better results for some outcome measures/". It is my clinical impression, howcver, that 12% is difficult for many paediatric patients to tolerate.
There have also been reports of an independent bacteriostatic effect of mesna with antibiotics such as carbenicilin and azlocillin, when used in vitro at a concentration of 1%. This effect is thought to be as a result of a direct impact on pseudomonal growth, rather than a potentiation of the antibiotic activityf".
Other mucoactive agents
Gelsolin Plasma gelsolin is found as a normal constituent of extracellular fluid. This protein rapidly cleaves non-covalent bonds within the actin filament of cellular actin and changes the characteristics of long entangled actin filaments from a gel-like sponge to a liquid or 'sol'-hence its name. Gelsolin in vitro appears to decrease sputum viscosity in CF and has the potential to act as a mucolytict''. DNase is also thought to possess the ability to bind to actin, but at a different site, and therefore gelsolin could theoretically result in activation of the nuclease activity on the actin-DNase complext", Clinical studies are awaited.
Mannitol
Mannitol induces an influx of water into the airway lumen and could act as an alternative non-ionic osmotic agent to hypertonic saline by improving the hydration of airway sccretions-/. A study using inhaled mannitol found an improvement in mucociliary clearance in six normal and six asthmatic patients'". In a follow-up pilot study, the clinical efficacy of mannitol (given as a 300 mg dry powder inhalation) was measured using the radioaerosollgamma camera technique for clearance monitoring. This was a small study (12 CF patients) and not powered to detect a difference, but mannitol proved equally as effective as HS for improvement in FEYt-It was ineffective for mucociliary clearance during the treatment period, with some improvement over placebo in post-intervention measure- Table 1 A selection of comparative studies of mucolytics ments. Like HS, mannitol demonstrated a bronchoconstrictor effectS!. Mannitol has potential as a mucolytic in CF. It can be delivered as a dry powder, and therefore delivery times could be less than for other nebulized mucolytics.
Amiforide
Amiloride is best known for its effect on promoting sodium reabsorption in the renal tubular cells. The inhibition of ion transport is complex and amiloride is likely to work on a number of sodium and calcium channels, including those in the trachea and large airways. Sputum viscosity and elasticity have been shown to be reduced in 14 out of 18 patients receiving aerosolized amiloride compared to placebo in a crossover design for 1 year. The aerosolized amiloride (5 mmollL as a 3.5 mL solution) was taken four times a day52. There was also a reduced rate of decline in lung function-'. But amiloride has a short duration of action and is rapidly absorbed, as it has no binding within the airway surface. For many patients an additional four nebulizations a day would not be practical. Amiloride has also been assessed in combination with normal saline54 and 7% HS29. The principles behind this regimen arc intriguing. By adding amiloride to saline there is the theoretical possibility that equilibration of the hypertonic fluid in the airway microenvironment will be prolonged and increase the duration of action of amiloride. However, in a mucociliary clearance trial the combination of amiloride and hypertonic saline did n~t lead to a significant additional difference in radioisotope clearance. Sadly, amiloride alone was not significantly different from isotonic salinc-",
WHICH MUCOLYTIC SHOULD I USE?
There is a dearth of comparative studies between the mucolytic agents. The difficulties from inadequately robust outcome measures and the marked individual variability in response to mucolytics bedevil such trials. There is also a reluctance by pharmaceutical companies to enter into comparative trials where the differences between two groups is unlikely to be significant-th~market is small and the number of patients required to provide adequate power for such investigations requires significant funding. A table of sample comparative trials (Table I) highlights the small numbers, differing outcome techniques and single-dose studies, e.g.:
• In a clinical trial of 27 children with Cf', Mistabron was compared with 7% saline solution. Although this was a double-blind crossover design, the difference in taste of the two products is likely to have unmasked the blinding process to a degree; A problem with washout effect between the two periods was also acknowledged. Although a number of the outcome measures showed no difference between the two agents, especially in children who were non-sputum producers, there was a statistically significant improvement in selected lung function measures for Mistabron over hypertonic saline 46
• DNase versus hypertonic saline: a short trial, published to date in abstract form only, compared 3 weeks of nebulized rhDNase with 5.85% HS. This was a randomized crossover design in 14 patients with mild to moderate disease. FEV t improved by 9.3%± 11.7% for DNase and by 7.7%± 14% for HS55. The mean inhalation time for the HS solution was 42 minutes, compared to 11 minutes for DNase. This led to less patient satisfaction with the HS • A longer-term trial compared 3 months' administration of DNase against HS in 43 children with CF. The two agents were given in random order, with a 2-week washout period. DNase produced a significant improvement in FEV] of 16% (SO 25%) from baseline compared with HS (3%; SO 21%P,56. This study also produced useful data that highlighted the variability of individual patient response within the study cohort ( Figure 3) . A selection of six individual patients illustrates this important feature ( 
THE n-of·1 STUDY
Large trials may show overall benefit 'for a group, but frequently there is considerable individual variation to response. Statistically significant mean results in large trials conceal wide individual variations in response. The recognition of this shortcoming led to the concept of the nof-I trial s7 , which is gaining increasing acceptance in clinical practice!", The approach tests for significant treatment effects within individuals using repeated measurements and a randomized double-blind placebo-controlled format. In designing such trials for mucolytics, most centres agree on the outcome measures, namely lung function and the patient's opinion. There is less agreement about the duration of these trials, with periods ranging from 2 weeks to 3 months S8 . DNase has already been the topic of a study using a protocol for targeted introduction through n-of-I trialsi", This was introduced in an effort to overcome the considerable and unpredictable variability of response of some cystic fibrosis patients to DNase. The method allowed patients to serve as their own controls and removed intersubject variability from the assessment data.
Physician treatment decisions are often influenced by the results, and the majority of patients rate n-of-I trials useful s7 ,6o .
CONCLUSION
The fact that mucolytics are required in CF at all is a reflection of our failure to address the underlying pathogenesis and control the downward spiral that leads to chronic lung disease in these patients. But until we are able to re-establish the normal surface milieu in the CFTRaltered airway chronic changes will happen, and with these changes there will be sputum production.
DNase, hypertonic saline and Mistabron are currently available mucolytics with the potential to assist in the clearance of tenacious sputum in CF lung disease. Clinical response is variable and highly individual; clinicians may need to consider a targeted trial to assess individual benefit. This concept of personalization of therapy is likely to play an increasingly important role in cystic fibrosis care.
